Upgrade to SI Premium - Free Trial

Pfizer (PFE) DMD Data Fall Short of Bar Set by Sarepta (SRPT) - Baird

May 15, 2020 9:39 AM
Baird analyst Brian Skorney reiterated an Outperform rating and $192.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) saying Pfizer's (NYSE ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA

Next Articles